Browse studies

Find your next paid study

27,332 recruiting studies available now

Targeted Upstream Prevention (T-UP): Engaging Vulnerable Students in Diabetes Prevention

The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students …

PrediabetesType 2 Diabetes

Estimated

~$10 – $750

Actual pay is set by the research site.

University of California, Los AngelesNCT07225218

Observational

Helpline Delivery of Brief Interventions for Postpartum Heavy Episodic Drinking

The pilot factorial trial will (1) evaluate feasibility, acceptability, and fidelity of the intervention components (Aim 2.1), and (2) collect proof-of-concept…

Heavy Drinking

Estimated

~$10 – $750

Actual pay is set by the research site.

The National Center on Addiction and Substance Abuse at Columbia UniversityNCT06591026

Phase 3

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0…

Untreated Follicular Lymphoma

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AstraZenecaNCT06549595

Phase 1

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemo…

Hemophilia B

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT06379789

Phase 3

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the effica…

Crohn's Disease

Estimated

~$50 – $2,250

Actual pay is set by the research site.

SanofiNCT07184931

Sample Collection From Healthy Volunteers for Assay Optimization

Background: The Laboratory of Immune System Biology (LISB) works with other labs at the National Institutes of Health. They study how parts of living things c…

Healthy Volunteers

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT03538600

Phase 3

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 year…

Moderate-to-Severe Atopic Dermatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Nektar TherapeuticsNCT07690371

Phase 2

Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study

The researchers are doing this study to find out whether it is practical (feasible) to stop treatment with ropeg-interferon (ropeg-INF) for some people with po…

Polycythemia Vera (PV)JAK2 Mutation

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07886801

Phase 1

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

This is a ﬁrst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efﬁcacy of CER-1236 in patients with relapsed/refrac…

AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$150 – $4,200

Actual pay is set by the research site.

CERo Therapeutics Holdings, Inc.NCT06834282

The FLOW Registry: Functional and Longitudinal Outcomes With Waterjet Ablation

The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquabla…

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $750

Actual pay is set by the research site.

University of ChicagoNCT07430423

Phase 1

A Multicenter, Sham-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Responses Following Stereotactic Intracranial Implantation of DSP-1083 Into Subjects With Parkinson's Disease

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female p…

Parkinson's Disease

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Sumitomo Pharma America, Inc.NCT06753331

Phase 1

Clinical Trial of D2C7-IT + 2141-V11 Combination Immunotherapy Administered Via Convection Enhanced Delivery in Non-enhancing Tumor Post-resection of Recurrent Glioblastoma, Followed by Cervical Perilymphatic Subcutaneous Injections of 2141-V11

The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with …

Recurrent Glioblastoma IDH Wildtype

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Darell BignerNCT06455605